NKY Acquired BioVision, Inc.
NKY Acquired BioVision, Inc.
BioVision, Inc., is a Life Science company headquartered in the beautiful San Francisco Bay area and founded in 1999. BioVision develops, produces and sells a wide variety of products including assay kits, recombinant proteins & enzymes, antibodies, small biological molecules, etc. Focusing on the field of bioanalysis related to disease and after years of accumulation, the company currently produces and sells more than 6000 kinds of products, which fully and systematically covers the biological research field such as cell metabolism, cell apoptosis, cell proliferation, cell stress, cell damage and repair, diabetes, obesity and metabolic syndrome, stem cell biology, gene regulation, gene signal transduction, etc. to provide global coverage of more than 70 of national life science researchers rich. BioVision is well known in life science industry to provide research tools to scientists in more than 70 counties worldwide to expedite their research. The cell metabolic kits and apoptosis kits developed by the company are highly specific, sensitive, fast and convenient, which has outstanding influence in related research fields. In the field of cell metabolism research, the company has the most complete product line containing sugar metabolism, lipid metabolism, protein and amino acid metabolism, enzyme activity and cofactor analysis. In the field of apoptosis, Annexin V kits enjoys a good reputation in global scientific research institutions. Meanwhile, the Caspase series provides the most complete types of products such as Caspase activity assay kit, Caspase protein kit, Caspase enzyme, Caspase inhibitor and substrate, etc. All kinds of research tools provided by the company could be applied to the study on the etiology and pathology, pharmaceutical effects of new medicine and pharmacological screening, development of diagnostic reagents, food nutrition analysis and environmental monitoring, etc. It’s mainly for research institutes, universities, hospital research department, biotechnology companies, pharmaceutical companies, drug testing companies, diagnostic reagents manufacturers, food manufacturers and environmental services company, etc.
The company has more than 60 employees, over 70% possess doctoral degrees, including over a total of 30 R & D technical staff, who come from global famous laboratory respectively, basically possessing doctoral degrees or above and deep academic foundation and research experience, and once published papers in core journals such as Nature, Journal of Biological Chemistry of Cell Biology, Journal of Cell Biology. Strong R & D strength supports the company to keep the leading R & D speed in the industry. The company can develop 100-200 new products and successfully launch them into the market every year, and always keep up with the latest research and development trend.
Focusing on the field of reagent for scientific research, the company has accumulated rich R & D experience of thousands of products, and has built up an efficient R & D system. Under the guidance of this system, the company's product development become orderly and systematized, which greatly improves the development efficiency. The company has accumulated a wealth of plasmid library, independently developed Pg-ProbeTM technology and various unique freeze-drying technologies, which make products more accurate, sensitive and convenient to use, forming a strong competitiveness.
Through establishing a solid cooperative relationship with world famous enterprises such as Sigma, Abcam and Fisher Scientific, the company has formed a sales network which radiates the main countries and regions in the world. Brand reputation has been continuously accumulated, and a batch of loyal customers has been developed. With the increasing importance on medical research attached by global governments and enterprises, the future market will be much wider.
Chinese Market Development Plan:
NKY Medical Group is acquiring BioVision, and will use BioVision's scientific research ability, production capacity and market channels to further develop its own biological medical business.